Damien  Mcdonald net worth and biography

Damien Mcdonald Biography and Net Worth

CEO of Enovis

Damien McDonald joined Enovis as the company’s CEO on May 12, 2025. An accomplished, results-driven and inclusive leader, Damien has more than 35 years of experience in the medical device industry. Prior to joining Enovis, he served as CEO of LivaNova, a global business creating clinically differentiated medical devices for the head and heart to improve the lives of patients worldwide. During his tenure there, he drove improved results in growth, profitability and shareholder value. He also made a meaningful impact on company culture, centered on a ‘Patients First’ mindset. Earlier in his career, Damien held leadership positions in MedTech, including Group Executive and Corporate Vice President for a $1.5 billion group of dental consumables companies at Danaher, led Zimmer’s spine division, and spearheaded global marketing for J&J’s Ethicon business unit. Damien has bachelor's degrees in pharmacy and economics from the University of Queensland, Australia. He also has a master’s degree in international economics from the University of Wales, Cardiff, U.K. and a Master of Business Administration from the Institute for Management Development, Lausanne, Switzerland.

What is Damien Mcdonald's net worth?

The estimated net worth of Damien Mcdonald is at least $2.78 million as of September 11th, 2025. Mcdonald owns 102,753 shares of Enovis stock worth more than $2,779,263 as of December 6th. This net worth evaluation does not reflect any other assets that Mcdonald may own. Learn More about Damien Mcdonald's net worth.

How do I contact Damien Mcdonald?

The corporate mailing address for Mcdonald and other Enovis executives is 2711 Centerville Road Suite 400, Wilmington DE, 19808. Enovis can also be reached via phone at 302-252-9160 and via email at [email protected]. Learn More on Damien Mcdonald's contact information.

Has Damien Mcdonald been buying or selling shares of Enovis?

Damien Mcdonald has not been actively trading shares of Enovis within the last three months. Most recently, on Thursday, September 11th, Damien Mcdonald bought 6,457 shares of Enovis stock. The stock was acquired at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the transaction, the chief executive officer now directly owns 102,753 shares of the company's stock, valued at $3,182,260.41. Learn More on Damien Mcdonald's trading history.

Who are Enovis' active insiders?

Enovis' insider roster includes Benjamin Berry (CFO), Christopher Hix (CFO), John Kleckner (Insider), Patricia Lang (SVP), Damien Mcdonald (CEO), A. Perfall (Director), Daniel Pryor (EVP), Brady Shirley (COO), Bradley Tandy (SVP), Matthew Trerotola (CEO & Chairman), and Rajiv Vinnakota (Director). Learn More on Enovis' active insiders.

Are insiders buying or selling shares of Enovis?

During the last year, Enovis insiders bought shares 4 times. They purchased a total of 14,625 shares worth more than $449,590.05. The most recent insider tranaction occured on November, 25th when insider John Kleckner bought 2,468 shares worth more than $74,829.76. Insiders at Enovis own 2.7% of the company. Learn More about insider trades at Enovis.

Information on this page was last updated on 11/25/2025.

Damien Mcdonald Insider Trading History at Enovis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/11/2025Buy6,457$30.97$199,973.29102,753View SEC Filing Icon  
See Full Table

Damien Mcdonald Buying and Selling Activity at Enovis

This chart shows Damien Mcdonald's buying and selling at Enovis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Enovis Company Overview

Enovis logo
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $27.05
Low: $26.73
High: $28.52

50 Day Range

MA: $30.46
Low: $26.87
High: $32.91

2 Week Range

Now: $27.05
Low: $25.47
High: $49.38

Volume

1,531,309 shs

Average Volume

740,468 shs

Market Capitalization

$1.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52